Trial Profile
Retrospective study comparing clinical outcomes of axitinib versus sunitinib as a first-line therapy for Metastatic Renal Cell Carcinoma in Japanese patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2018
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 21 May 2018 Results presented at the 113th Annual Meeting of the American Urological Association
- 17 May 2018 New trial record